Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study

被引：0
|
作者：
Han Eol Jeong
Sohee Park
Yunha Noh
Sungho Bea
Kristian B. Filion
Oriana H. Y. Yu
Seung Hun Jang
Young Min Cho
Dong Keon Yon
Ju-Young Shin
机构：
[1] Sungkyunkwan University,School of Pharmacy
[2] Sungkyunkwan University,Department of Biohealth Regulatory Science
[3] Biostatistics,Departments of Medicine and of Epidemiology
[4] and Occupational Health,Centre for Clinical Epidemiology
[5] McGill University,Division of Endocrinology and Metabolism
[6] Lady Davis Institute,Division of Pulmonary, Allergy, and Critical Care Medicine, College of Medicine
[7] Jewish General Hospital,Department of Internal Medicine
[8] Jewish General Hospital,Department of Translational Medicine
[9] McGill University,Department of Internal Medicine
[10] Hallym University Sacred Heart Hospital,Institute On Aging
[11] Hallym University,Department of Pediatrics
[12] Seoul National University College of Medicine,Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST)
[13] Seoul National University College of Medicine,undefined
[14] Seoul National University Hospital,undefined
[15] Seoul National University,undefined
[16] Medical Science Research Institute,undefined
[17] Kyung Hee University College of Medicine,undefined
[18] Kyung Hee University Medical Center,undefined
[19] Kyung Hee University College of Medicine,undefined
[20] Sungkyunkwan University,undefined
来源：
BMC Medicine | / 21卷
关键词：
Sodium-glucose cotransporter 2 inhibitors; Respiratory effectiveness; Type 2 diabetes; Population-based cohort;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes
    Siamashvili, Maka
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2181 - 2198
  • [32] Risk of insulin initiation with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A real-world claims database study in Japan
    Suzuki, Ryo
    Shoji, Shingo
    Yoshinaga, Yoko
    Kosakai, Yoshinori
    Shintani-Tachi, Mami
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1960 - 1971
  • [33] Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes
    Yanai, Hidekatsu
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 9 (05) : 117 - 119
  • [34] Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study
    Hu, Wei-Syun
    Lin, Cheng-Li
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (01) : 575 - 581
  • [35] New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors: A Chinese population-based cohort study
    Gao, X.
    Zhang, N.
    Gao, T.
    Tse, G.
    Lip, G. Y. H.
    Liu, T.
    Zhou, J.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [36] Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Yu, Teng-Shun
    Hung, Yu-Tung
    Hsu, Chih-Cheng
    Hwu, Chii-Min
    JAMA NETWORK OPEN, 2023, 6 (12) : E2348431
  • [37] Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary C.
    Zakoul, Heidi
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 265 - 274
  • [38] The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
    Ling, Ann Wan-Chin
    Chan, Cze-Ci
    Chen, Shao-Wei
    Kao, Yi-Wei
    Huang, Chien-Ying
    Chan, Yi-Hsin
    Chu, Pao-Hsien
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [39] Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study
    Ng, Pauline Yeung
    Ng, Andrew Kei-Yan
    Ip, April
    Wu, Mei-Zhen
    Guo, Ran
    Yiu, Kai-Hang
    CRITICAL CARE MEDICINE, 2023, 51 (08) : 1073 - 1084
  • [40] Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
    Sharma, M. D.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 616 - 621
12345